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JOURNAL OF HEPATOLOGYReply to: ‘‘Lower incidence of hepatocellular carcinoma in
patients with transient virologic response to peginterferon
and ribavirin combination therapy: Is it really the effect
of the therapy?’’To the Editor:
We appreciate the interest shown in our study by Toyoda et al.
and thank them for their comments [1]. Due to space limitations,
we were unable to report extensive details of viral and host fac-
tors, including hepatitis C virus (HCV) core protein and interleu-
kin 28B (IL28B) genotype. We fully agree that the amino acid (aa)
substitutions at position 70 in the HCV core region are associated
with poor virological response to pegylated interferon a (PegIFN-
a) and ribavirin (RBV) treatment, hepatic steatosis, insulin resis-
tance, and development of hepatocellular carcinoma (HCC). We
also previously reported that the diversity of the HCV core region
is signiﬁcantly correlated with abnormal alanine aminotransfer-
ase (ALT) levels [2]. Unfortunately, we do not have information
on the HCV core antigen sequence of the studied patients because
this was a multicenter study that was started before publication
of the ﬁndings of oncogenic potential by treatment-resistant sub-
stitution of core aa 70 (glutamine/histidine) [3]. Although substi-
tutions in the core region might affect the development of HCC,
analysis of a ﬁxed condition such as this, is difﬁcult because the
sequence of the core region sometimes changes with time [4]
or during antiviral treatment [5]. Recently, deep sequencing has
become available for the determination of viral genetic varia-
tions. According to this technology, treatment-resistant substitu-
tion of core aa 70 was found to be contained in most cases, even
when not detected by direct sequencing. The structural and func-
tional alterations of core protein and the relation to the occur-
rence of HCC need to be further studied.
We reported that the incidence rate of HCC for patients with
IL28B TT (rs8099917) genotype after antiviral treatment was sig-
niﬁcantly lower than that for patients with non-TT genotype, asJournal of Hepatology 20Toyoda et al. reported [6]. However, there was no signiﬁcant dif-
ference in the incidence rate of HCC in patients who had not
received antiviral treatment between the IL28B TT and non-TT
genotypes [4], despite the fact that the IL28B non-TT genotype
was related to treatment-resistant substitution of core aa 70.
Therefore, further studies are needed to determine the mecha-
nisms related to HCV core aa 70, IL28B genotype, and the devel-
opment of HCC.
We concluded that transient virological response (TVR) was
associated with a lower risk of development of HCC in compari-
son with the non-virological response (NVR) in a prospective
study and emphasized that this association was observed not
only for cirrhotic patients, but also for non-cirrhotic patients aged
60 years and over. We did not merely suggest that TVR was
directly reducing HCC development. In our discussion, we stated
the possibility of the efﬁcacy of viral suppression compared with
previous studies. In addition, TVR patients have sometimes
redounded to benign clinical outcomes. For instance, our study
showed that the percentage of TVR patients who developed hepa-
tic decompensation was lower than that of NVR patients, and
Morgan et al. showed similar ﬁndings to our study [7]. Moreover,
the rate of biochemical response (BR; ALT <30 IU/L at six months
after the antiviral treatment) of TVR was signiﬁcantly higher than
that of NVR (36.2% vs. 17.1%, p <0.001). BR in non-sustained viro-
logical response (non-SVR) patients has been reported to contrib-
ute to the inhibition of the development of HCC [8]. In fact, our
study showed that the HCC incidence rate of BR/TVR was signif-
icantly lower than that of non-BR/TVR patients (0.9% vs. 6.2%,
p <0.05). We previously reported that the liver stiffness measure-
ments by transient elastography (FibroScan) of BR/non-SVR13 vol. 58 j 831–843 839
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Letters to the Editor
patients decreased continuously for two years after the end of
treatment [9]. Therefore, an additional effect of TVR may be that
it leads to lower risk of the development of HCC.
In summary, our study conﬁrmed a lower incidence of HCC in
patients with TVR compared to those with NVR, probably because
TVR was associated with benign clinical outcomes.
We thank the Journal of Hepatology for providing the opportu-
nity for us to engage in this interesting discussion.
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To the Editor:
Howell and colleagues [1] have recently provided important
insights into the relationship among viral kinetic patterns,
including the triphasic pattern (Fig. 1 in [1]), ethnicity (African
Americans, AA, and Caucasian Americans, CA) and IL28B geno-
types (rs12979860; CC, TC and TT genotypes) during pegylated
interferon-alpha-2a (PegIFNa-2a) + ribavirin (RBV) treatment.
Their study strongly suggested differences in viral kinetic pat-
terns under PegIFNa-2a ± RBV between AA and CA are associated
with IL28B genotypes and elegantly showed that the difference
disappears in AA or CA subjects with the same favorable allele
(CC). Interestingly, Howell et al. described subjects in whom a
static or increasing viral phase (termed here a shoulder) was
observed during days 2–7 after treatment initiation (Fig. 1 in
[1]). While the nature of the shoulder phase is still not known,
Howell et al. [1] related this phase to ‘‘a delay in the pharmaco-
logic activity of ribavirin’’ or ‘‘lower PegIFNa-2a effectiveness’’.
We sought here to clarify the current theory behind the nature
of the shoulder phase and provide further insights into the
subject.
A transient viral decline was observed in some HCV-monoin-
fected subjects during the ﬁrst week of RBV monotherapy [2]. In a
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recent study, in which subjects were treated with RBV alone for
4 weeks, there was no association between HCV RNA kinetics
measured weekly and IL28B genotypes (submitted). In HIV/HCV
co-infected subjects treated with PegIFNa-2b and RBV, median
RBV area under the curve levels were lower in sustained viral
responders (SVRs) compared with non-SVRs at days 3 and 7
and were associated with a continued viral decline during days
3–7 (in SVRs) compared to a shoulder in non-SVRs (Fig. 2C in
[3]). Unfortunately, data on IL28B genotypes is not yet available
to be linked to our previous studies [2,3], but if indeed subjects
with IL28B CC genotypes in Howell et al. are associated with early
lower RBV levels and/or transient viral decline during the ﬁrst
week, then it could, partly, explain their ﬁndings.
A more evident cause of the viral shoulder phase is the known
pharmacokinetics of PegIFNawhich peaks and then declines dur-
ing the ﬁrst week of treatment [4,5]. To explain the shoulder
phase with the standard model [6], the PegIFNa concentration
in serum, C(t), was coupled with its effectiveness, e(t), in blocking
viral production/release [4,5] (see Fig. 1 for equations and param-
eters deﬁnition). Using this theory, the observed viral kinetic pat-
terns from Howell et al. can be predicted (Fig. 1). Interestingly, we
recently showed, in HIV/HCV (genotype 1/3) co-infected subjects
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